Cargando…

A Pilot Genome‐Wide Analysis Study Identifies Loci Associated With Response to Obeticholic Acid in Patients With NASH

A significantly higher proportion of patients with nonalcoholic steatohepatitis (NASH) who received obeticholic acid (OCA) had histological improvement relative to placebo in the FLINT (farnesoid X nuclear receptor ligand obeticholic acid for noncirrhotic, NASH treatment) trial. However, genetic pre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gawrieh, Samer, Guo, Xiuqing, Tan, Jingyi, Lauzon, Marie, Taylor, Kent D., Loomba, Rohit, Cummings, Oscar W., Pillai, Sreekumar, Bhatnagar, Pallav, Kowdley, Kris V., Yates, Katherine, Wilson, Laura A., Chen, Yii‐Der Ida, Rotter, Jerome I., Chalasani, Naga
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887685/ https://www.ncbi.nlm.nih.gov/pubmed/31832568 http://dx.doi.org/10.1002/hep4.1439

Ejemplares similares

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Relationship of ELF and PIIINP With Liver Histology and Response to Vitamin E or Pioglitazone in the PIVENS Trial
por: Gawrieh, Samer, et al.
Publicado: (2021)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Obeticholic acid and INT-767 modulate collagen deposition in a NASH in vitro model
por: Anfuso, Beatrice, et al.
Publicado: (2020)

Validation of the accuracy of the FAST(™) score for detecting patients with at-risk nonalcoholic steatohepatitis (NASH) in a North American cohort and comparison to other non-invasive algorithms
por: Woreta, Tinsay A., et al.
Publicado: (2022)

Imaging biomarkers of NAFLD, NASH, and fibrosis
por: Ajmera, Veeral, et al.
Publicado: (2021)

A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2018)

Automated assessment of steatosis in murine fatty liver
por: Sethunath, Deepak, et al.
Publicado: (2018)

Integrative omics analysis identifies macrophage migration inhibitory factor signaling pathways underlying human hepatic fibrogenesis and fibrosis
por: Liu, Zhipeng, et al.
Publicado: (2019)

A randomized, placebo-controlled, phase II study of obeticholic acid for primary sclerosing cholangitis
por: Kowdley, Kris V., et al.
Publicado: (2020)

Obeticholic Acid Modulates Serum Metabolites and Gene Signatures Characteristic of Human NASH and Attenuates Inflammation and Fibrosis Progression in Ldlr‐/‐.Leiden Mice
por: Morrison, Martine C., et al.
Publicado: (2018)

Metabolomic Study of High-Fat Diet-Induced Obese (DIO) and DIO Plus CCl(4)-Induced NASH Mice and the Effect of Obeticholic Acid
por: Zhu, Nanlin, et al.
Publicado: (2021)

Current therapies and new developments in NASH
por: Dufour, Jean-François, et al.
Publicado: (2022)

Dynamic Alterations to Hepatic MicroRNA-29a in Response to Long-Term High-Fat Diet and EtOH Feeding
por: Liang, Tiebing, et al.
Publicado: (2023)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH
por: Hydes, Theresa J., et al.
Publicado: (2020)

Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist
por: Guzman, Cristina B., et al.
Publicado: (2018)

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH
por: Roth, Jonathan D., et al.
Publicado: (2019)

Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden
por: Dakhoul, Lara, et al.
Publicado: (2018)

Changing Trends of Cirrhotic and Noncirrhotic Hepatocellular Carcinoma in the Era of Directly-Acting Antiviral Agents
por: Mathur, Karan, et al.
Publicado: (2021)

TERN-101, a farnesoid X receptor agonist, demonstrated similar safety and efficacy in non-alcoholic steatohepatitis patients with coronavirus disease of 2019 (COVID-19) exposure compared to those with no COVID-19 exposure in phase 2a LIFT study
por: Lawitz, Eric, et al.
Publicado: (2022)

Serum Hepcidin Levels Are Associated With Obesity but Not Liver Disease
por: Vuppalanchi, Raj, et al.
Publicado: (2013)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
por: Loomba, Rohit, et al.
Publicado: (2020)

Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease
por: Kleiner, David E., et al.
Publicado: (2019)

The Liver in Systemic Illness
por: Chalasani, Naga, et al.
Publicado: (2006)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Distinctive Features and Outcomes of Hepatocellular Carcinoma in Patients With Alcohol-Related Liver Disease: A US Multicenter Study
por: deLemos, Andrew, et al.
Publicado: (2020)

GDF8 Contributes to Liver Fibrogenesis and Concomitant Skeletal Muscle Wasting
por: Culver, Alexander, et al.
Publicado: (2023)

Glycogenosis is common in nonalcoholic fatty liver disease and is independently associated with ballooning, but lower steatosis and lower fibrosis
por: Allende, Daniela S, et al.
Publicado: (2021)

Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD
por: Bazick, Jessica, et al.
Publicado: (2015)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
por: Yan, Kathleen, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5411i0m5fjl9kqiqle6v7239fr